Rosenblatt maintains Buy rating on Imax, $65 price target
Rosenblatt maintained a Buy rating and $65 price target on Imax, implying a 25.8% upside. The firm cited strong box office performance, with Q3 Gross Box Office at $712 million, up 94% YoY, driven by 'The Odyssey'. Analysts expect continued growth from upcoming film releases.
How this was made

The 30-second read
Why it matters
The new target suggests a sizable upside, likely prompting short‑term buying.
Market read
Analyst upgrade and higher target could move IMAX stock in the near term.
What to watch
Potential supply constraints at IMAX locations and macro‑economic headwinds could limit upside.
Background
Rosenblatt maintains a Buy rating on IMAX with a $65 price target after reporting record quarterly box office results.
Ticker impact
Rosenblatt upgraded its rating to Buy and set a new $65 price target, implying 25.8% upside from the recent close.
likely upward pressure as investors price in the new target
The note provides fresh guidance and a concrete upside estimate, which can influence short‑term demand.
Market effects
May lift sentiment for the cinema and entertainment exhibition sector.
Primarily U.S. market impact; limited regional effect.
Modest global relevance, confined to IMAX and peers.
Counterpoint
The price target may be overly optimistic given competitive streaming pressures.
Key entities
- AnalystRosenblatt
Equity research firm issuing the rating and target.
- CompanyIMAX Corp
Cinema technology and exhibition company.



